Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase NA × copper dotatate CU-64 × Clear all

Phase

Phase 2 2 Phase NA 1 Phase 3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Neuroendocrine Tumors 1

Interventions

Exercise 355 Blood Specimen Collection 284 Standard of Care 265 Magnetic Resonance Spectroscopy 231 Radiotherapy 220 Radiosurgery 206 Surveys and Questionnaires 203 Educational Status 195 Methods 192 Early Intervention, Educational 173 Practice Guidelines as Topic 124 Interviews as Topic 121 Biopsy 119 Drug Therapy 115 Control Groups 114 Surgical Procedures, Operative 113 Acupuncture Therapy 109 Cyclophosphamide 88 Therapeutics 87 Palliative Care 85 Counseling 85 Magnetic Resonance Imaging 76 Resistance Training 75 Saline Solution 73 Cisplatin 72 Radiofrequency Ablation 71 Radiotherapy, Intensity-Modulated 70 Specimen Handling 67 Colonoscopy 67 Cognitive Behavioral Therapy 65

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02125474 2019-11-14

Efficacy of 177-Lu-DOTA 0, Tyr 3 Octreotate

Instituto Nacional de Cancerologia, Columbia

Phase NA Completed

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡